Introduction to Novo Nordisk and its Obesity Treatment
Novo Nordisk, a renowned pharmaceutical company based in Denmark, has been working on an innovative oral obesity treatment called semaglutide. This new pill, if approved, could become the first oral GLP-1 treatment for weight management in the United States.
New Clinical Trial Data: OASIS 4
At the ObesityWeek 2025 in Atlanta, Novo Nordisk presented new data from the OASIS 4 clinical trial. The results demonstrated that the oral semaglutide 25 mg pill provides cardiovascular benefits and comparable weight loss to the successful injectable Wegovy.
Clinical Trial Results
- 71.1% of participants with prediabetes who took the pill achieved normal blood glucose levels after 64 weeks, compared to 33.3% on a placebo.
- Patients who lost at least 15% of their body weight experienced greater improvements in blood pressure, reductions in inflammatory markers, and triglyceride levels.
Comparison with Previous STEP 1 Injectable Trial
An indirect comparison between the OASIS 4 trial and the previous STEP 1 injectable Wegovy trial showed that both oral and injectable formulations offered comparable results in terms of weight loss goals and cardiometabolic markers.
Regulatory Progress and Future Plans
The U.S. Food and Drug Administration (FDA) accepted Novo Nordisk’s request for Wegovy oral in May, with a decision expected by the end of the fourth quarter. Novo Nordisk anticipates approval and plans to launch the pill shortly afterward.
Despite recent financial adjustments due to stagnant sales growth, Novo Nordisk has secured a better-than-expected Medicare pricing agreement. The company is navigating a turbulent period marked by declining stock prices and slowing sales growth, which led to leadership changes and board restructuring.
Potential Distribution Channels
Once approved, Novo Nordisk intends to distribute the pill through telehealth platforms such as Ro and WeightWatchers. The company is also exploring a subscription model with discounts.
Hims & Hers Health recently announced that it is in talks with Novo Nordisk to offer both injectable and oral Wegovy through its platform. The pill showed a 16.6% weight loss in the primary results of OASIS 4, published in September in the New England Journal of Medicine.
Key Questions and Answers
- What is Novo Nordisk’s oral obesity pill? The pill, called semaglutide, is an experimental treatment for weight management developed by Novo Nordisk.
- What are the key findings from the OASIS 4 trial? The trial showed that oral semaglutide 25 mg provides cardiovascular benefits and comparable weight loss to the injectable Wegovy.
- When can we expect FDA approval? The FDA is expected to make a decision by the end of the fourth quarter of 2025.
- How will Novo Nordisk distribute the pill? The company plans to use telehealth platforms like Ro and WeightWatchers, as well as explore a subscription model with discounts.
- What partnerships is Novo Nordisk pursuing? The company is in talks with Hims & Hers Health to offer both injectable and oral Wegovy through its platform.
